A fixed combination of grazoprevir and elbasvir for the treatment of hepatitis c virus infection

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: YOO, Bong-Kyu (College of Pharmacy, Gachon University, Inchon, Korea, Republic Of)
  • Co-author(s): Bong-Kyu Yoo:
    Min-Gu Kang: College of Pharmacy, Gachon University, Incheon, Korea, Republic Of
    Min-Jung Kang: College of Pharmacy, Gachon University, Incheon, Korea, Republic Of
    Eun Kyung Choi: College of Pharmacy, Gachon University, Incheon, Korea, Republic Of
    Eunhee Ji: College of Pharmacy, Gachon University, Incheon, Korea, Republic Of
  • Abstract:

    Methods

    Data of the pivotal Phase III clinical studies retrieved from PubMed, EMBASE, Drug@FDA and ClinicalTrials.gov website were evaluated regarding primary/secondary endpoints and safety. 

    Results

    When patients with HCV were treated with GE for 12 weeks, the sustained virologic response, defined as the viral RNA level below the lower limit of..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login